Our hydrogel technology is a versatile platform employed to create sustained-release therapies that may expand treatment options across multiple ocular conditions.
The hydrogel delivery technology enables the use of drugs that are known to be safe and eﬃcacious when formulated as drops or injections by creating sustained release dosage forms.
Key Attributes of the Hydrogel Platform
Sustained Release Drug Delivery
The hydrogel is currently being used in research and development to encapsulate a wide range of ophthalmic pharmaceuticals with the goal of delivering sustained therapeutic levels of drug to targeted ocular tissues.
Ocular’s intracanalicular inserts can be placed through the punctum for ocular surface or anterior segment therapies. The hydrogel can also be engineered as implants that can be injected intracamerally for anterior segment therapies or intravitreally for posterior segment therapies.
The hydrogel platform has the potential to expand the utility of therapeutic molecules with the objective of:
The hydrogel platform can be engineered to address specific needs across ocular surface, anterior segment and posterior segment, such as:
A cataract is a clouding of the lens inside the front of the eye. During cataract surgery, a patient’s cloudy natural lens is removed and replaced with a prosthetic intraocular lens. Clear corneal incisions allowing entry to the eye are the standard of care for performing cataract surgery. The most common post-surgical approach is to allow the incisions to self-seal, or close, through normal biological processes. However, self-sealing incisions can open spontaneously, especially within 12 to 24 hours following surgery, when intraocular pressure fluctuates or as a result of the application of external pressure or manipulation. Complications from fluid leakage include the development of hypotony, or low intraocular pressure, which can lead to corneal decompensation and vision loss, as well as increased susceptibility to infection. The implanted lens also may shift in position due to hypotony, leading to poor visual outcomes following surgery.
Post-operative pain and inflammation are common side effects following any ophthalmic surgery. Due to this, physicians prescribe anti-inflammatory therapies, such as corticosteroids, following ocular surgery as the standard of care. This not only helps manage the symptoms, but also provides faster recovery for the patient.
Allergic conjunctivitis is an inflammatory-mediated ocular surface disorder induced by allergen. Most approved therapies for ocular allergy, such as topical antihistamines and mast cell stabilizers, act to reduce the signs and symptoms of the early phase allergic reaction. However, there is evidence that patients with ocular allergy exhibit a persistent late phase reaction. Corticosteroids effectively treat the clinical signs and symptoms of acute and chronic allergy, and are particularly effective in treating late phase ocular allergic reactions.
OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION
Glaucoma is a group of eye conditions that are often associated with elevated intraocular pressure. Over time, this high pressure leads to degeneration of cells in which make up the optic nerve, slowly decreasing vision. It is a chronic condition which cannot be reversed, and therefore must be monitored for life.
Compliance is seen as the biggest problem with existing therapies for glaucoma, and more than 50% of patients on topical prostaglandin analogs are not adherent with their therapy within the first six months of treatment.¹
RETINAL NEOVASCULAR DISEASES
Retinal diseases such as age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic macular edema (DME) can be devastating to eyesight, causing central and/or peripheral vision loss. AMD is one of the most common retinal diseases, and is the leading cause of blindness in the United States.²
Current therapies for retinal diseases have been shown to manage the progression of these diseases to prevent further vision loss and in some cases gain visual acuity, however, they require frequent intraocular injections.
¹ Nordstrom B, Friedman D, Mozaffari E, et al. Persistence and Adherence With Topical Glaucoma Therapy. Am J Ophthalmol. 2005;140:589.e1–11.
² “Vision Problems in the US. Prevalence of Adult Vision Impairment and Age-related Eye Disease in America”. National Eye Institute, Prevent Blindness America, © 2012. Web. October 11, 2017.